SAINT-PREX, Switzerland, Jan 23 (Bernama-BUSINESS WIRE) — Ferring Pharmaceuticals today announced that Propess® (dinoprostone) has been approved by the Minister of Health, Labour and Welfare (MHLW) in Japan for initiation of cervical ripening in patients at term (from 37 completed weeks of gestation).1 This is the first time in over 20 years that a pharmacological therapy for cervical ripening has been approved in the country.2
Around 10 per cent of births globally require induction of labour, which may be required if the health of the mother or baby is at risk.3,4 Cervical ripening is carried out prior to induction to prepare the cervix for birth. This approval offers women requiring an induction in Japan greater choice of alternatives to mechanical methods of cervical ripening.
http://mrem.bernama.com/viewsm.php?idm=36612
